Expand DGX Menu
DGX MENU

DGX Latest Press Releases

-- April 2, 2024 --

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay PRNewswire 7:57 AM

-- March 26, 2024 --

Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease PRNewswire 7:09 AM

-- March 19, 2024 --

Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024 PRNewswire 3:06 PM

-- February 23, 2024 --

Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference PRNewswire 9:35 AM

-- February 21, 2024 --

Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery PRNewswire 7:58 AM

-- February 15, 2024 --

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection PRNewswire 6:00 AM

-- February 13, 2024 --

Quest Diagnostics Debuts MelaNodal Predict Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery PRNewswire 8:07 AM

-- February 12, 2024 --

First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com PRNewswire 8:01 AM

-- February 1, 2024 --

Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share PRNewswire 6:45 AM

-- January 31, 2024 --

Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies" PRNewswire 2:50 PM

-- January 22, 2024 --

Haystack Oncology, developer of Haystack MRD , and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma PRNewswire 8:07 AM

-- January 17, 2024 --

Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 PRNewswire 9:35 AM
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health PRNewswire 8:58 AM

-- January 9, 2024 --

Quest Diagnostics and Ultima Collaborate to Scale Ultima's Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing Business Wire 8:05 AM

-- January 8, 2024 --

Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System PRNewswire 8:56 AM
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD technology in phase II clinical trial for unresectable stage III NSCLC PRNewswire 7:07 AM

-- December 21, 2023 --

Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference PRNewswire 1:04 PM

-- December 20, 2023 --

Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer PRNewswire 7:34 AM

-- December 19, 2023 --

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel PRNewswire 8:54 AM

-- December 14, 2023 --

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD in Clinical Study of Early-Stage Triple-Negative Breast Cancer PRNewswire 8:53 AM

-- December 7, 2023 --

Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States PRNewswire 8:01 AM

-- December 6, 2023 --

Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year PRNewswire 9:04 AM

-- November 28, 2023 --

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis PRNewswire 8:40 AM

-- November 20, 2023 --

Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States PRNewswire 8:53 AM